The revamp of French drugmaker Ipsen has continued with a takeover agreement for US counterpart Epizyme and its cancer therapy Tazverik, in a deal valued at a little under $250 million.
The US regulator has approved Epizyme’s Tazverik (tazemetostat) for advanced sarcoma, providing a new option for a disease where there are high recurrence rates and toxicity issues with est
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh